FDA moves BPC-157 to Category 1 by…?
As of Wed, 18 Nov 2026 23:32:23 UTC, Polymarket traders price Yes (5.5%). The market has $4K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 5.5% | 5.5¢ | 94.5¢ |
Market details
- Venue: Polymarket
- Volume: $4K
- Liquidity: $805
- Closes:
Resolution rules
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Sources
Related markets
- Venezuela leader end of 2026?
- Who will be Trump's next Press Secretary?
- Who will leave their role in the Trump administration this year?
- Will Trump buy at least part of Greenland?
- Will marijuana be rescheduled?
- Will the House impeach Trump?
More markets like this
- Which of these people will be impeached first by the end of 2027?
- FDA approves Retatrutide this year?
- Heidi Overton confirmed as FDA Commissioner by...?
- Plague case in US by December 31?
- Fed abolished before 2027?
- Fed Decision in April?
- Fed Decision in December?
- Fed Decision in January?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.